Literature DB >> 8874079

Nonsurgical cure of isolated cerebral mucormycosis in an intravenous drug user.

R Blázquez1, A Pinedo, J Cosín, P Miralles, C Lacruz, E Bouza.   

Abstract

The case of a 30-year-old, female, HIV-positive intravenous drug user who suffered from isolated cerebral mucormycosis is reported. Treatment with amphotericin B at an accumulative dose of 5.5 grams led to significant recovery, and there was no recurrence of disease over a follow-up period of six months. Patients with isolated cerebral mucormycosis in whom surgery would be a high-risk or impossible procedure could be managed medically with prolonged courses of intravenous amphotericin B.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8874079     DOI: 10.1007/bf01709370

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  10 in total

1.  Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 52-1990. A 31-year-old HIV-seropositive woman with a cerebral lesion seven years after treatment of carcinoma of the cervix.

Authors: 
Journal:  N Engl J Med       Date:  1990-12-27       Impact factor: 91.245

2.  Localization and fate of Absidia ramosa spores after intravenous inoculation of mice.

Authors:  J M Smith; R H Jones
Journal:  J Comp Pathol       Date:  1973-01       Impact factor: 1.311

3.  Mucormycosis.

Authors: 
Journal:  Lancet       Date:  1986-06-14       Impact factor: 79.321

Review 4.  Mucormycosis.

Authors:  A M Sugar
Journal:  Clin Infect Dis       Date:  1992-03       Impact factor: 9.079

5.  Mucormycosis. Report of 11 cases.

Authors:  R Rangel-Guerra; H R Martínez; C Sáenz
Journal:  Arch Neurol       Date:  1985-06

Review 6.  Isolated central nervous system mucormycosis.

Authors:  S U Siddiqi; J D Freedman
Journal:  South Med J       Date:  1994-10       Impact factor: 0.954

Review 7.  Isolated cerebral mucormycosis: case report and therapeutic considerations.

Authors:  R Gollard; C Rabb; R Larsen; P Chandrasoma
Journal:  Neurosurgery       Date:  1994-01       Impact factor: 4.654

8.  Improved diagnosis and prognosis of mucormycosis. A clinicopathologic study of 33 cases.

Authors:  N A Parfrey
Journal:  Medicine (Baltimore)       Date:  1986-03       Impact factor: 1.889

Review 9.  Zygomycosis of the basal ganglia in intravenous drug users.

Authors:  G M Stave; T Heimberger; T M Kerkering
Journal:  Am J Med       Date:  1989-01       Impact factor: 4.965

Review 10.  Cerebral mucormycosis associated with intravenous drug use: three case reports and review.

Authors:  R J Hopkins; M Rothman; A Fiore; S E Goldblum
Journal:  Clin Infect Dis       Date:  1994-12       Impact factor: 9.079

  10 in total
  6 in total

1.  A 28-year-old i.v. drug user with bilateral basal ganglia and brainstem lesions.

Authors:  Tanya P Lin; Rebecca Thompson; Bruce Coull
Journal:  Neurology       Date:  2013-02-12       Impact factor: 9.910

2.  Pulmonary mucormycosis due to Lichtheimia ramosa in a patient with HIV infection.

Authors:  Murat Kutlu; Cağrı Ergin; Ferda Bir; Süleyha Hilmioğlu-Polat; Ramazan Gümral; Ceyda Necan; Ali Koçyiğit; Selda Sayın-Kutlu
Journal:  Mycopathologia       Date:  2014-06-13       Impact factor: 2.574

3.  Isolated cerebral mucormycosis.

Authors:  Seong Rok Han; Chan Young Choi; Mee Joo; Choong Jin Whang
Journal:  J Korean Neurosurg Soc       Date:  2007-11-20

4.  Isolated cerebellar mucormycosis, slowly progressive over 1 year in an immunocompetent patient.

Authors:  Ellen L Air; Achala A Vagal; Ady Kendler; Christopher M McPherson
Journal:  Surg Neurol Int       Date:  2010-12-13

5.  Zygomycosis in Immunocompromised non-Haematological Patients.

Authors:  George Petrikkos; Miranda Drogari-Apiranthitou
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-03-15       Impact factor: 2.576

6.  Isolated Cerebral Mucormycosis in Immunocompetent Adults who Inject Drugs: Case Reports and Systematic Review of the Literature.

Authors:  Eric A Meyerowitz; Sarimer Sanchez; Michael K Mansour; Virginia A Triant; Marcia B Goldberg
Journal:  Open Forum Infect Dis       Date:  2020-11-13       Impact factor: 3.835

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.